Boehringer Ingelheim Faces Legal Heat as Zantac’s Toxic Risks Come to Light
Chicago, Illinois — A colorectal cancer patient claimed in an Illinois courtroom that Boehringer Ingelheim failed to address knowledge of serious safety concerns regarding the active ingredient in its over-the-counter drug Zantac. The patient asserted that the company took insufficient actions despite years of warnings that the compound could degrade into a harmful substance. During the trial, the plaintiff recounted their experience with Zantac, alleging that the pharmaceutical company merely altered the color of its tablets rather than addressing the underlying issues. The patient’s testimony raises questions about Boehringer Ingelheim’s commitment to consumer safety and … Read more